Introduction {#sec1}
============

Colorectal cancer (CRC) is the second and third most commonly diagnosed cancer type in females and males, respectively. The GLOBOCAN 2018 estimates for both sexes combined, the incidence and mortality rates of 10.2 and 9.2 per 100,000, respectively \[[@cit0001]--[@cit0003]\]. There are slightly more incident cases and deaths among men than women in most parts of the world, except in the Caribbean \[[@cit0004]\]. In Taiwan, according to 2015 cancer registry data, the age-standardized incidence rates of CRC for males and females became 52.1 and 34.9 people per 100,000 population, respectively. The CRC mortality rate in 2017 was 24.7 per 100,000 population \[[@cit0005]\].

Cancer survival is an indicator of the overall effectiveness of health services in the management of patients. Studies showed that the 5-year survival rate of individuals with CRC was 65% in the United States. Early disease identification and treatment with newer agents would likely improve the survival of high-risk CRC patients; the 5-year survival rate of stage I and II CRC ranges from 80% to 90%, whereas stage III and IV metastatic diseases are associated with 5-year survival rates of 60--71% and 8--13%, respectively \[[@cit0006], [@cit0007]\]. Currently, in Taiwan, the overall 5-year survival rate of CRC is 63.0% \[[@cit0008]\]. Fang *et al.* \[[@cit0009]\] found that the 5-year survival rate was 74.3% for stage I CRC compared with 76.6% for stage II, 56.6% for stage III and only 16.7% for stage IV.

Colorectal cancer is considered primarily a "lifestyle" disease. The literature shows that demographic variables, such as age, gender, familial CRC history, diets high in calories and animal fat, alcohol consumption, and obesity, in addition to other factors, such as tumor site, size, grade, histologic type, TNM stage, and carcinoembryonic antigen (CEA) level, have all been found to significantly affect survival in CRC \[[@cit0003], [@cit0010]--[@cit0013]\]. In the present study, we used population-based data from the Taiwan Cancer Database of the medical center hospital in North Taiwan to compare socio-demographic and clinic-pathological characteristics, prognostic factors, and overall survival between 2 groups of CRC patients, i.e., those with the colon or rectum as the primary site.

Chewing betel nuts in Taiwan is a unique characteristic of this culture. Previous studies have demonstrated that retaining and subsequently swallowing betel quid juice and unripened betel fruit in the quid both increase the risks of contracting oral cancer \[[@cit0014]\]. Because swallowing betel nut juice will affect the gastrointestinal tract, we added chewing betel nuts as a factor in demographic variables to explore whether it affects survival of CRC patients. This study aimed to explore the survival rate and the potential factors influencing survival among CRC, colon cancer and rectum cancer patients in northern Taiwan. The research questions involved were as follows:

1.  What is the 5-year survival rate of colon cancer and rectum cancer in this area?

2.  Does smoking, drinking, or chewing betel nuts affect survival in this population?

3.  What are the risk factors affecting the survival of CRC, colon cancer and rectum cancer?

Material and methods {#sec2}
====================

Study population {#sec2.1}
----------------

In this study, we conducted a single-center, retrospective cohort study to estimate the survival outcome of patients diagnosed with colorectal carcinoma at Cathay General Hospital in North Taiwan between 2007 and 2013. Data were extracted from medical records and the cancer database by trained data collectors. The eligibility criteria included the following: diagnosis and treatment of CRC; the International Classification of Disease for Oncology, 3^rd^ edition (ICD-O-3) topographical codes of C18.0--C20.9 (excluding C18.1) and morphology codes of 8000--8152, 8154--8231, 8243--8245, 8247--8248, 8250--8576, 8940--8950 and 8980--8981. Participants who showed more than one type of cancer, ICD-O-3 morphology codes of 8935--8936, 8153, 8240--8242, 8013, 8246, 8249 and 9590--9720, a T~X~N~X~M~X~ stage of 888 or 999, BBB case, or a survival time of less than six months were excluded. Demographic data extracted included gender, age at diagnosis, body mass index (BMI), smoking history, betel nut chewing status, drinking habits, and date of last contact or death. The evaluated tumor characteristics included primary site, histologic type, grade/differentiation, and size, as well as treatment type and regional lymph node or distant organ metastasis. The disease staging was based on the American Joint Committee on Cancer (AJCC) criteria; cancer site-specific factors included CEA, circumferential resection margin (CRM), tumor regression grade, perineural invasion, obstruction and perforation. Survival data were obtained using death and date of last contact records to determine the current situation or date of death of each patient.

Ethics {#sec2.2}
------

The study was reviewed and approved by the hospital's institutional review board (No. CGH-P104060).

Statistical analysis {#sec2.3}
--------------------

Statistical analyses were performed using SPSS software (version 22.0 of SPSS). Survival time was calculated as the time from diagnosis to the censoring date or the date of death. Continuous variables are described by summary statistics, such as the mean, standard deviation (SD) and percentage (%). The data were also analyzed using Kaplan-Meier curves, and differences between the curves were analyzed by the log-rank test. Cox proportional hazards regression models were used to analyze survival by each variable.

Results {#sec3}
=======

Sample characteristics {#sec3.1}
----------------------

A summary of the demographic and clinical characteristics of the participants is presented in [Table I](#t0001){ref-type="table"}. The follow-up period continued to December 2015. We retrospectively evaluated 869 patients from 2007 to 2013. The majority of the patients were male, and the median age at diagnosis was 64 years (range: 17--97). Approximately 43.04% of the patients had normal BMI values (18.5--24 kg/m^2^), while 386 (44.42%) were either overweight or obese (BMI ≥ 24 kg/m^2^). Only 14.4%, 18.04%, and 3.45% of patients had a drinking, smoking and eating/chewing betel nut history, respectively. We found that 554 (63.75%) patients were diagnosed with cancer of the colon. The most common histopathology type reported was adenocarcinoma (91.71%), and 34.87% (colon: 32.49%; rectum: 39.05%) of patients had stage III disease at the time of diagnosis, while 27.39% had stage II (colon: 30.14%; rectum: 22.54%). Regional lymph node involvement and distant metastasis were found in 45.22% and 14.04% of patients, respectively. More than 50% of patients had no obstruction at presentation. Only 5.45% of patients had postoperative CRM.

###### 

Demographic and clinical characteristics of colorectal cancer patients (*N* = 869)

  Parameter                                  Overall *n* (%)        Colon *n* (%)          Rectum *n* (%)
  ------------------------------------------ ---------------------- ---------------------- ----------------------
  Gender:                                                                                  
   Male                                      454 (52.40)            271 (48.92)            183 (58.10)
   Female                                    415 (47.76)            283 (51.08)            132 (41.90)
  Age:                                                                                     
   Mean (range) \[years\]                    71.27 ±1.27 (17--97)   71.90 ±1.58 (17--93)   67.88 ±1.95 (26--97)
   \< 65 years old                           435 (50.06)            261 (47.11)            174 (55.24)
   ≥ 65 years old                            434 (49.94)            293 (52.89)            141 (44.76)
  BMI:                                                                                     
   18.5--24 kg/m^2^                          374 (43.04)            301 (54.33)            151 (47.94)
   ≥ 24 kg/m^2^                              386 (44.42)            192 (34.66)            116 (36.83)
   Unknown                                   109 (12.54)            61 (11.01)             48 (15.23)
  Smoking:                                                                                 
   No                                        602 (69.28)            407 (73.47)            (61.90)
   Yes                                       160 (18.41)            87 (15.70)             73 (23.17)
   Unknown                                   107 (12.31)            90 (10.83)             46 (14.93)
  Drinking:                                                                                
   No                                        642 (73.88)            421 (75.99)            221 (70.16)
   Yes                                       122 (14.04)            74 (13.36)             48 (15.24)
   Unknown                                   105 (12.08)            59 (10.65)             46 (14.60)
  Chewing betel nut:                                                                       
   No                                        733 (84.35)            479 (86.46)            254 (80.63)
   Yes                                       30 (3.45)              15 (2.71)              15 (4.76)
   Unknown                                   106 (12.20)            60 (10.83)             46 (14.61)
  Pathological tumor status:                                                               
   T1/T2                                     231 (26.58)            134 (24.19)            97 (30.79)
   T3                                        468 (53.86)            285 (51.44)            183 (58.11)
   T4                                        170 (19.56)            135 (24.37)            35 (11.11)
  Cancer stage:                                                                            
   I                                         190 (21.86)            113 (20.40)            77 (24.44)
   II                                        238 (27.39)            167 (30.14)            71 (22.54)
   III                                       303 (34.87)            180 (32.49)            123 (39.05)
   IV                                        138 (15.88)            94 (16.97)             44 (13.97)
  Histopathology type:                                                                     
   Adenocarcinoma                            797 (91.71)            493 (89.71)            300 (95.24)
   Mucinous carcinoma                        64 (7.36)              53 (9.57)              11 (3.49)
   Signet ring-cell carcinoma                8 (0.92)               4 (0.72)               4 (1.27)
  Distant metastasis:                                                                      
   No                                        747 (85.96)            470 (84.84)            277 (87.94)
   Yes                                       122 (14.04)            84 (15.16)             78 (12.06)
  Number of regional lymph nodes involved:                                                 
   No                                        476 (54.78)            316 (57.04)            160 (50.79)
   Yes                                       393 (45.22)            238 (42.96)            155 (49.21)
  No. of lymph nodes examined:                                                             
   \< 12                                     222 (25.55)            132 (23.83)            90 (28.57)
   ≥ 12                                      647 (74.45)            422 (76.17)            225 (71.48)
  Pathological differentiation:                                                            
   Low grade                                 773 (89.0)             478 (86.28)            295 (93.65)
   High grade                                96 (11.0)              76 (13.72)             20 (6.35)
  Tumor size:                                                                              
   \< 50 mm                                  528 (60.41)            341 (61.55)            187 (59.37)
   ≥ 50 mm                                   281 (32.15)            185 (33.39)            96 (30.48)
   Unknown                                   60 (7.44)              28 (5.06)              32 (10.15)
  CEA:                                                                                     
   \< 5.0 ng/ml                              34 (3.91)              6 (1.08)               5 (1.59)
   ≥ 5.0 ng/ml                               692 (79.63)            448 (79.42)            275 (87.30)
   Unknown                                   143 (6.46)             108 (19.50)            35 (11.11)
  CRM:                                                                                     
   Negative                                  826 (94.55)            520 (93.87)            296 (93.97)
   Positive                                  47 (5.45)              30 (5.41)              17 (5.40)
   Unknown                                   6                      4 (0.72)               2 (0.63
  KRAS mutation:                                                                           
   No                                        43 (4.95)              29 (5.2)               14 (4.4)
   Yes                                       25 (2.88)              20 (3.6)               51.6)
   Unknown                                   801 (92.17)            505 (91.2)             296 (94.6)
  Perineural invasion:                                                                     
   No                                        496 (54.68)            287 (51.80)            163 (51.75)
   Yes                                       373 (45.32)            267 (48.20)            152 (48.25)
  Obstruction:                                                                             
   No                                        512 (58.92)            312 (56.32)            200 (63.49)
   Yes                                       357 (41.08)            242 (43.63)            115 (36.51)
  Perforation:                                                                             
   No                                        853 (98.16)            543 (98.01)            310 (98.41)
   Yes                                       16 (1.84)              11 (1.79)              5 (1.51)

Survival outcome {#sec3.2}
----------------

The mean survival time was 71.27 ±1.27 months (colon group 71.90 ±1.58 months; rectum group 67.88 ±1.95 months) ([Table II](#t0002){ref-type="table"}). The 5-year survival rates for CRC, colon cancer and rectum cancer were 68.66%, 69.11% and 67.90%, respectively. There was no significant difference (*p* = 0.493) between patients who had colon or rectum cancer ([Figure 1](#f0001){ref-type="fig"}). The 5-year survival rates for CRC patients who had stage I, II, III or IV cancer were 91.20%, 82.20%, 63.20% and 21.70%, respectively ([Figure 2](#f0002){ref-type="fig"}). The 5-year survival rate of colon cancer at stage I, II, III and IV was 94.40%, 82.30%, 65.00% and 22.60%, respectively. In the rectum group, the rates were 87.00%, 82.10%, 60.80% and 22.90%, respectively. Log rank tests showed that cancer stage was associated significantly with survival rate (*p* \< 0.001).

###### 

One, three and five-year relative survival and mean survival for colorectal cancer patients

  Survival                         Relative survival rate (%)   Mean survival \[months\]   95% CI
  -------------------------------- ---------------------------- -------------------------- --------------
  Colorectal cancer (*n* = 869):                                71.27 ±1.27                68.79--73.75
   1-year                          95.28                                                   
   3-year                          79.45                                                   
   5-year                          68.66                                                   
  Colon cancer (*n* = 554):                                     71.90 ±1.58                68.80--75.00
   1-year                          95.56                                                   
   3-year                          80.56                                                   
   5-year                          69.11                                                   
  Rectum cancer (*n* = 315):                                    67.88 ±1.95                64.55--71.71
   1-year                          94.79                                                   
   3-year                          77.56                                                   
   5-year                          67.90                                                   

![**A** -- Kaplan-Meier curves of patients with colon and rectum cancer. **B** -- Kaplan-Meier curves of colorectal cancer by stage of disease](AMS-16-1-38460-g001){#f0001}

![**A** -- Kaplan-Meier curves of colon cancer by stage of disease. **B** -- Kaplan-Meier curves of rectum cancer by stage of disease](AMS-16-1-38460-g002){#f0002}

From the univariate Cox regression model, factors considered effective for CRC 5-year survival were age at diagnosis, tumor status, regional lymph node metastasis, distant organ metastasis, cancer stage, pathological differentiation, perineural invasion, tumor size, KRAS mutation, CRM, obstruction, and perforation (all *p* \< 0.05). Site-specific analyses of colon and rectum cancer for confounders were also performed. However, there were no significant differences in perforation, CEA, and BMI or smoking, drinking, and betel nut chewing behavior for the two groups. Details are shown in [Table III](#t0003){ref-type="table"}.

###### 

Cox regression univariate analysis

  Parameter                         Colorectal cancer Univariate analysis   Colon cancer Univariate analysis   Rectum cancer Univariate analysis                          
  --------------------------------- --------------------------------------- ---------------------------------- ----------------------------------- -------------- ------- -------------
  Age:                                                                                                                                                                    
   \< 65 years old                                                                                                                                                        
   ≥ 65 years old                   1.87                                    1.42--2.47                         1.98                                1.38--2.85     1.77    1.15--2.72
  Tumor status:                                                                                                                                                           
   T1/T2                                                                                                                                                                  
   T3                               8.74                                    5.23--14.60                        9.94                                4.75--20.79    3.44    1.75--6.76
   T4                               3.54                                    2.16--5.82                         3.9                                 1.88--8.16     11.35   5.23--24.62
  Regional lymph node metastasis:                                                                                                                                         
   No                                                                                                                                                                     
   Yes                              3.05                                    2.29--4.05                         2.39                                1.95--2.93     1.83    1.43--2.36
  Distant organ metastasis:                                                                                                                                               
   No                                                                                                                                                                     
   Yes                              5.57                                    4.16--7.45                         6.24                                4.34--8.98     4.75    2.88--7.81w
  Cancer stage:                                                                                                                                                           
   I                                                                                                                                                                      
   II                               2.55                                    1.34--4.86                         3.21                                1.23--8.36     2.32    0.95--5.70
   III                              5.01                                    2.73--9.18                         6.68                                2.66--16.80    3.94    1.75--8.88
   IV                               18.96                                   10.28--34.96                       26.27                               10.45--66.02   14.41   6.17--33.67
  Histology type:                                                                                                                                                         
   Adenocarcinoma                                                                                                                                                         
   Mucinous carcinoma               1.77                                    1.16--2.71                         8.13                                2.99--22.10    2.12    0.923--4.87
   Signet ring-cell carcinoma       2.80                                    1.04--7.55                         1.75                                1.07--2.89     0.000   0.000--3.71
  Pathological differentiation:                                                                                                                                           
   Low grade                                                                                                                                                              
   High grade                       2.20                                    1.56--3.10                         2.22                                1.48--3.34     2.44    1.26--4.72
  Tumor size:                                                                                                                                                             
   \< 50 mm                                                                                                                                                               
   ≥ 50 mm                          1.53                                    1.15--2.03                                                                            2.03    1.29--3.18
  KRAS mutation:                                                                                                                                                          
   No                                                                                                                                                                     
   Yes                              3.90                                    1.45--10.51                        0.27                                0.09--0.83     0.28    0.03--2.35
  CRM:                                                                                                                                                                    
   Negative                                                                                                                                                               
   Positive                         2.18                                    1.43--3.31                         2.12                                1.23--3.63     2.42    1.25--4.71
  Perineural invasion:                                                                                                                                                    
   No                                                                                                                                                                     
   Yes                              4.43                                    3.22--6.10                         4.46                                2.95--6.73     4.31    2.59--7.17
  Obstruction:                                                                                                                                                            
   No                                                                                                                                                                     
   Yes                              1.87                                    1.43--2.44                         1.93                                1.37--2.73     1.79    1.17--2.75
  Perforation:                                                                                                                                                            
   No                                                                                                                                                                     
   Yes                              2.28                                    1.07--4.84                                                                                    

As shown in [Table IV](#t0004){ref-type="table"}, the risk of CRC death was high among patients with age ≥ 65 years (HR = 2.36, 95% CI: 1.76--3.17); high grade of pathological differentiation (HR = 1.84, 95% CI: 1.27--2.66); perineural nerve invasion (HR = 2.90, 95% CI: 2.03--4.14); metastasis to distant organs (HR = 2.78, 95% CI: 2.00--3.87); intestinal obstruction (HR = 1.38, 95% CI: 1.04--1.84); and regional lymph node metastasis (HR = 1.81, 95% CI: 0.28--2.57). The risk of colon and rectum cancer deaths for patients aged ≥ 65 years was 2.87 (95% CI: 1.91--4.30) and 2.39 (95% CI: 1.49--3.83); that of high grade of pathological differentiation was 1.73 (95% CI: 1.09--2.75) and 2.59 (95% CI: 1.27--5.29); that of perineural invasion was 2.60 (95% CI: 1.62--4.10) and 4.16 (95% CI: 2.29--7.57); and that of metastasis to distant organs was 3.21 (95% CI: 2.09--4.92) and 2.48 (95% CI: 1.39--4.42). Regional lymph node metastasis was only found to be significant in the colon cancer group (HR = 1.86, 95% CI: 1.44--2.39). A tumor size ≥ 50 mm (HR = 1.65, 95% CI: 1.03--2.63) significantly predicted rectum cancer death.

###### 

Forward stepwise Cox regression analysis

  Parameter                         Colorectal cancer Univariate analysis   Colon cancer Univariate analysis   Rectum cancer Univariate analysis                       
  --------------------------------- --------------------------------------- ---------------------------------- ----------------------------------- ------------ ------ ------------
  Age:                              2.36                                    1.76--3.17                         2.87                                1.91--4.30   2.39   1.49--3.83
   \< 65 years old                                                                                                                                                     
   ≥ 65 years old                                                                                                                                                      
  Pathological differentiation:     1.84                                    1.27--2.66                         1.73                                1.09--2.75   2.59   1.27--5.29
   Low grade                                                                                                                                                           
   High grade                                                                                                                                                          
  Perineural invasion:              2.90                                    2.03--4.14                         2.60                                1.65--4.10   4.16   2.29--7.57
   No                                                                                                                                                                  
   Yes                                                                                                                                                                 
  Distant metastasis:               2.78                                    2.00--3.87                         3.21                                2.09--4.92   2.48   1.39--4.42
   No                                                                                                                                                                  
   Yes                                                                                                                                                                 
  Obstruction:                      1.38                                    1.04--1.84                                                                                 
   No                                                                                                                                                                  
   Yes                                                                                                                                                                 
  Regional lymph node metastasis:   1.81                                    1.28--2.57                         1.86                                1.44--2.39          
   No                                                                                                                                                                  
   Yes                                                                                                                                                                 
  Tumor size:                                                                                                                                                   1.65   1.03--2.63
   \< 50 mm                                                                                                                                                            
   ≥ 50 mm                                                                                                                                                             

Discussion {#sec4}
==========

This study observed factors connected with disease survival in a population-wide cohort with access to universal healthcare, with a specific focus on recognizing the 5-year survival rate and risk factors of CRC, colon cancer, and rectum cancer. In the present study, the 1, 3, and 5-year relative survival rates of CRC were better than those in Malaysia and other countries, such as Singapore, Korea, Iran, and India \[[@cit0015], [@cit0016]\]. In the present study, the 5-year survival rate was 68.66% in CRC patients, 69.11% in colon cancer patients and 67.90% in rectum cancer patients, similar to the findings of Moghimi-Dehkordi and Safaee \[[@cit0016]\] and Fang *et al.* \[[@cit0017]\]. Certain characteristics related to disease progression were strongly associated with the 5-year risk of death from CRC: age ≥ 65 years, high grade of pathological differentiation, perineural nerve invasion, distant metastasis, obstruction and multiple regional lymph node metastases; each independently increased the risk of death by factors of 1.38 to almost 3. In the present study, we found that BMI, smoking, drinking, and chewing betel nut were not significant predictors of CRC, colon cancer, or rectum cancer survival. This may be explained by different lifestyle practices and changing dietary patterns. However, our study did not include information on diet and physical activity level. On the other hand, it may be related to the different proportions of colon and rectum cancer patients in the different studies. Further research should be undertaken to collect these data and assess these factors.

Colorectal cancer, colon cancer, and rectum cancer were more frequently found in men than women. In the present study, more than half of the subjects were male, but gender was not found to be a significant factor related to overall survival analyses. Similarly, Fang *et al.* \[[@cit0009]\] and Çetin *et al.* \[[@cit0018]\] established in previous studies that gender was not a significant prognostic factor. Younger age is a positive prognostic factor. In the present study, after adjustment for the relevant control variables, we found that age ≥ 65 years old was associated with an increased risk of death of 2.36 (95% CI: 1.76--3.17). Similarly, Fang *et al.* \[[@cit0009]\], Wang *et al.* \[[@cit0013]\], and Kornprat *et al.* \[[@cit0019]\] reported that patient age at diagnosis appears to be an important prognostic factor for all patients. Previous studies found that younger patients had a worse prognosis \[[@cit0020]\] because patients younger than 50 years did not qualify for screening and likely presented symptomatic disease and had a poorer prognosis. Therefore, reducing the age at which patients should be screened for this condition could lead to improved outcomes. Such strategies as fecal occult blood testing using immunochemical methods could easily be implemented. In the current studies, when controlling for tumor stage, patient, and treatment factors, young patients had a superior overall survival.

The overall 5-year survival rate in the present study was 68.70%; this result is better than that reported by the HPA \[[@cit0005]\], Fang *et al.* \[[@cit0009]\] in Taiwan, and the American Cancer Society, which estimated survival rates of 63.0%, 55.69%, and 66%, respectively. In the present study, the overall stage-specific 5-year survival rate for stage I--IV was 91.20%, 82.20%, 63.20%, and 21.70%, respectively. Mathur *et al.* \[[@cit0007]\] reported that stage I and stage II CRC have an 80--90% 5-year survival rate, whereas stage III and stage IV metastatic diseases are associated with 5-year survival rates of 60% and 8%, respectively. In comparison, the survival rates found in the present study were higher than those previously reported. The risk of death in stage II, III, and IV CRC compared to stage I was 2.55 (95% CI: 1.34--4.86, *p* \< 0.001), 5.01 (95% CI: 2.73--9.18, *p* \< 0.001), and 18.96 (95% CI: 10.28--34.96, *p* \< 0.001), respectively. Similarly, studies by Kao *et al.* \[[@cit0021]\] and Tsai *et al.* \[[@cit0022]\] supported the conclusion that the number of regional lymph node metastases in CRC is an important factor of CRC survival. In addition to AJCC stage, it is possible that other factors influence the survival rate. Thus, previous studies estimating the survival rate investigated pathology results, such as tumor site, size, grade, histology, regional lymph node metastases, perineural invasion and other variables in addition to the AJCC stage, T stage, N stage, and M stage as independent variables \[[@cit0020], [@cit0021], [@cit0023], [@cit0024]\].

In most cases, early-stage CRC does not present obvious symptoms; as such, muscle infiltration or distant metastases have occurred by the time of diagnosis. In this study, we found that tumor status, regional lymph node metastasis, and distant metastasis independently affect the survival rate of CRC patients. These results are consistent with CRC survival rate estimates reported by Zare-Bandamiri *et al.* \[[@cit0025]\], Agüero *et al.* \[[@cit0026]\], and Yuan *et al.* \[[@cit0027]\]. The present findings show that high-grade pathological differentiation was associated with a relative excess hazard for death of 1.84 (95% CI: 1.27--2.66, *p* = 0.001). Similarly, Zare-Bandamiri *et al.* \[[@cit0025]\], Yuan *et al.* \[[@cit0027]\], and Kinoshita *et al.* \[[@cit0028]\] reported that grade level can independently affect the survival rate of CRC patients. This finding indicates that early CRC staging has a positive effect on survival rate. Therefore, the earlier detection of CRC should lead to substantial improvements in survival. Some researchers have suggested that CRC screenings should begin at \< 50 years of age \[[@cit0009], [@cit0013], [@cit0023]\].

In the present study, univariate analysis revealed that histology type was an important factor. There were significant percentages of mucinous adenocarcinoma (7.36%) and signet-ring cell carcinoma (0.92%). These findings are similar to those of previous CRC studies \[[@cit0009], [@cit0023], [@cit0027]\]. The results showed that the risk of death in mucinous adenocarcinoma and signet-ring cell CRC with adenocarcinoma was 1.77 (95% CI: 1.16--2.71, *p* = 0.008) and 2.80 (95% CI: 1.04--7.55, *p* = 0.042), respectively. These results support the findings of Fang *et al.* \[[@cit0009]\] and Yuan *et al.* \[[@cit0027]\], who found that the histology type of CRC was a risk factor for mortality. However, in the forward stepwise Cox regression analysis, histology type did not independently affect the survival rate of CRC patients.

In this study, we found that perineural invasion was associated with a relative excess hazard for death of 4.43 (95% CI: 3.22--6.10, *p* \< 0.001). Furthermore, our forward stepwise Cox regression analysis showed that perineural invasion was associated with improved predictions of CRC prognosis, which was in agreement with previous reports \[[@cit0009], [@cit0029]--[@cit0031]\]. After adjustment with the relevant control variables, we found that peripheral invasion remained an independent predictor of patient survival and prognosis. The importance of this factor should be considered by clinicians when assessing the prognosis of patients.

Previous studies showed that obstruction was a significant factor affecting the survival of CRC patients. In the present study, the univariate Cox regression analysis demonstrated better survival in patients without obstruction (HR = 1.87, 95% CI: 1.43--2.44, *p* \< 0.001). After adjustment for the relevant control variables, we found that obstruction was associated with a relative excess hazard for death of 1.38 (95% CI: 1.04--1.84, *p* = 0.026). These findings are similar to those of Cennamo *et al.* \[[@cit0032]\] and Fu *et al.* \[[@cit0033]\].

In conclusion, we found that perineural invasion, distant metastasis, age, pathological differentiation grade, obstruction and regional lymph node metastasis are independent predictors of the survival and prognosis of patients with CRC. Perineural invasion and distant metastasis appeared to be important prognostic factors affecting the entire patient cohort, and the earlier detection of CRC would improve patient survival. One limitation of this study was the small sample size; in addition, the findings were generated using data from a single medical center hospital in North Taiwan. Thus, the results of some survival comparisons were not significant. These limitations should be considered when applying these results to other districts in Taiwan that may have demographic differences. Furthermore, multicenter studies should be conducted to merge patient datasets for further research in Taiwan.
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